In a nutshell This study looked at the effectiveness of bortezomib plus cyclophosphamide and rituximab at treating patients with relapsed mantle cell lymphoma. The study concluded that this combination of medication is safe and effective at treating patients with relapsed or difficult to treat mantle cell lymphoma. Some background Mantle...
Read More
In a nutshell This study looked at how effective the combination of bendamustine plus rituximab was at treating patients with indolent B-cell non-Hodgkin lymphoma (B-NHL) and mantle cell lymphoma (MCL). The study concluded that bendamustine plus rituximab is safe and effective for treating patients with indolent B-NHL and MCL. Some...
Read More
In a nutshell This study looked at the use of lenalidomide (Revlimid) treatment for patients with relapsed mantle cell lymphoma. The authors concluded that lenalidomide is generally safe and effective for treating patients with advanced stage relapsed or difficult to treat mantle cell lymphoma. Some background Mantle cell lymphoma (MCL) is an...
Read More
In a nutshell This phase 3 clinical trial will test the effectiveness of a lenalidomide (Revlimid) and rituximab (Rituxan) maintenance therapy followed by rituximab and lenalidomide or rituximab only in treating relapsed follicular, marginal zone, or mantle cell lymphoma. The primary outcome will be measured by the time to disease progression....
Read More
In a nutshell This phase 1 clinical trial will test the safety of a JCAR014 engineered T cells and durvalumab (MEDI4736) combination in treating recurrent or refractory (unresponsive to treatment) non-Hodgkin’s lymphoma. The primary outcome will be measured by evaluating the movement of the engineered T cells throughout the body and side...
Read More
In a nutshell This phase 3 clinical trial will test the effectiveness of ibrutinib (Imbruvica) during and after stem cell transplant in patients with relapsed or refractory diffuse large B-cell lymphoma. The primary outcome will be measured by the time to disease progression. The details Ibrutinib is a drug that stops the growth of...
Read More
In a nutshell This phase 1/2 clinical trial will test the response to AFM13 in patients with relapsed or refractory cutaneous (on the skin) CD30 positive lymphomas. The primary outcome will be measured by immune system activity. This study will be conducted at the Center for Lymphoid Malignancies in New York, New York. The details AFM13 is an...
Read More
In a nutshell The authors looked at the effect of rituximab (Rituxan) treatment after autologous stem cell transplantation in patients with mantle cell lymphoma. The authors concluded that the use of rituximab after autologous stem cell transplantation improves outcomes for patients with mantle cell lymphoma. Some background Mantle cell...
Read More
In a nutshell This study compared the outcomes of different treatment options for stage 1 follicular lymphoma (FL). This study concluded that different treatment approaches were all associated with good outcomes. Some background FL is the second most common form of non-Hodgkin lymphoma diagnosed in the United States. 26% of patients are...
Read More
In a nutshell This study examined whether bone marrow biopsies are necessary if PET scans are used to stage classical Hodgkin lymphoma. The study concluded that patients can safely be staged with PET/CT scans without bone marrow biopsy. Some background Hodgkin lymphoma (HL) is widely considered a curable disease. Between 4 and 11% of patients with...
Read MoreIn a nutshell This study provided a long-term follow-up of patients diagnosed with early-stage Hodgkin lymphoma. The study concluded that current strategies for reduced intensity treatment of early-stage Hodgkin lymphoma are generally safe and effective. Some background Hodgkin lymphoma (HL) is generally considered a curable disease....
Read More
In a nutshell This study explored whether treatment with rituximab (Rituxan) improved outcomes and quality of life compared to a watch and wait approach in patients with advanced-stage, follicular lymphoma without symptoms. The authors determined that treatment with rituximab was a safe and effective treatment option. Some background Some patients...
Read More
